<DOC>
	<DOCNO>NCT00712491</DOCNO>
	<brief_summary>The purpose study determine safety efficacy ocular sirolimus ( rapamycin ) formulation via different injection route patient treatment-naive sub-foveal choroidal neovascularization secondary age-related macular degeneration .</brief_summary>
	<brief_title>Phase 1/2 Study Ocular Sirolimus ( Rapamycin ) Formulation Patients With Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria include , limited : Diagnosed subfoveal choroidal neovascularization secondary agerelated macular degeneration Visual acuity 20/50 20/200 study eye Any ocular disease could compromise vision study eye History prior treatment choroidal neovascularization study eye Presence cause choroidal neovascularization secondary agerelated macular degeneration</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>wet AMD</keyword>
	<keyword>CNV</keyword>
</DOC>